Yahoo Finance Reports
Clinical trials on the hallucinogenic drug DMT for the treatment of depression are expected to start in January.
According to The Guardian, the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) gave the green light to the Imperial College of London, in partnership with neuropharmaceutical research company Small Pharma, to begin the trials.
DMT, a strong, short-acting hallucinogenic compound, remains illegal in the UK as in most countries around the globe. It is best known as the active ingredient in ayahuasca, a hallucinogenic drink traditionally used as a spiritual medicine in shamanic ceremonies among indigenous communities in South America.
This would be the first time DMT is studied in the treatment of clinical depression.
The institutions stated that the essays will be based on recent clinical research on psilocybin, the active psychedelic compound in magic mushrooms.
In its initial phase, 32 healthy volunteers will be given DMT in order to understand the minimum dose needed to achieve a psychedelic effect. After that, the drug will be administered to 36 separate patients, who have been diagnosed with clinical depression.
The parties still await Home Office approval given the scheduled condition of the drug.